Will insurance cover Zepbound for sleep apnea?

FDA, December 20, 2024: "the U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity, to be used in combination with a reduced-calorie diet and increased physical activity." The agency called it "the first drug treatment option for certain patients with obstructive sleep apnea."

US Food and Drug Administration, news release, effective December 2024 · source

Zepbound's label: "ZEPBOUND® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity." The sleep apnea dose: "10 mg or 15 mg injected subcutaneously once weekly."

DailyMed (National Library of Medicine), Zepbound prescribing information, effective August 2026 · source

CMS, in its memo on the Medicare GLP-1 Bridge: "Part D plan sponsors must continue to provide coverage of GLP-1 drugs for indications that are currently coverable under Medicare Part D" and "must not deny or limit access to GLP-1 drugs in a manner that improperly encourages use of the Medicare GLP-1 Bridge." "For example, beneficiaries prescribed Zepbound® for the treatment of moderate to severe obstructive sleep apnea in adults with obesity … should continue to receive coverage through Medicare Part D." A Bridge request attesting sleep apnea "will be denied."

Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge expectations and FAQs (HPMS memorandum), effective June 2026 · source

CMS: "Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring (fibrosis) indications are eligible for Part D coverage. Beneficiaries with these diagnoses are eligible to receive GLP-1s through their Part D plan and therefore are ineligible to receive them through the Medicare GLP-1 Bridge." A prescription "to reduce the risk of major adverse cardiovascular events … should be routed to the Part D plan." For these uses, "Part D plan sponsors must continue to follow their existing formulary exception processes."

Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge: information for Part D plans, effective August 2026 · source

Lilly's Medicare page: "Medicare GLP-1 Bridge covers Zepbound KwikPen for obesity/weight management only." "Medicare Part D covers GLP-1s for several health conditions … so if you have one of those conditions, you are not eligible for the Medicare GLP-1 Bridge program." Its eligibility checklist adds: "Your Part D plan may cover moderate-to-severe OSA or other conditions."

Eli Lilly and Company, Zepbound and Medicare, effective June 2026 · source

Lilly's Zepbound savings card terms require that "You are not enrolled in any state, federal, or government funded healthcare program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medicare Advantage, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state prescription drug assistance program." You must also be "a resident of the United States or Puerto Rico" and "18 years of age or older."

Eli Lilly and Company, Zepbound Savings Card terms and conditions, effective August 2026 · source

Zepbound has the same arrangement through a different door. Its non-formulary program repeats that "Medications for the purpose of weight loss are typically a benefit exclusion," and then states: "The program allows for coverage of Zepbound for obesity with obstructive sleep apnea." It requires a sleep study, a BMI of at least 30, and either continued symptoms despite adherent positive airway pressure therapy or a reason you cannot use it.

UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Non-Formulary – Zepbound (tirzepatide) – Obstructive Sleep Apnea Only" (2026 P 1475-3), effective September 2026 · source

UnitedHealthcare's Zepbound sleep apnea program (2026 P 1475-3, effective September 1, 2026) requires "BMI ≥ 30 kg/m2"; moderate-to-severe sleep apnea shown by "a sleep study" with an apnea-hypopnea index, respiratory event index or respiratory disturbance index above 15 events per hour; "At least one previous unsuccessful dietary effort to lose weight"; continued symptoms despite positive airway pressure therapy used "≥ 4 hours of use per night for ≥ 70 percent of nights", or not being a candidate for it; no diagnosis of diabetes; and a sleep specialist, pulmonologist, otolaryngologist or a physician experienced in sleep apnea as prescriber. "Authorization will be issued for 6 months." Renewal requires "a weight loss of greater than or equal to 10% of baseline body weight".

UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Non-Formulary – Zepbound (tirzepatide) – Obstructive Sleep Apnea Only" (2026 P 1475-3), effective September 2026 · source

Cigna's benefit-exclusion override policy for GLP-1s (IP0621, effective April 30, 2026) opens: "Weight loss medications are specifically excluded under many benefit plans", then says it "authorizes coverage non-weight loss based on FDA-approved indications as applicable." Its sleep apnea criteria approve Zepbound for one year for a patient 18 or older with a baseline BMI of at least 30 and "a sleep study" showing moderate to severe obstructive sleep apnea with "an apnea-hypopnea index ≥ 15 events per hour", and not central sleep apnea. Renewal after a year requires having "lost ≥ 10% of baseline body weight".

Cigna Healthcare, Drug Coverage Policy IP0621, "Weight Loss – Glucagon-Like Peptide-1 Agonists BMI ≥ 32" (Benefit Exclusion Overrides), effective April 2026 · source

Aetna's commercial Zepbound criteria (6947-C, P04-2025, dated July 1, 2025) grant authorization for sleep apnea when "The patient has an established diagnosis of moderate to severe OSA with an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT)" and "a current body mass index (BMI) greater than or equal to 30 kg/m2." Renewal needs "a positive response to treatment from baseline, evidenced by a decrease in OSA symptoms."

Aetna, "Zepbound PA with Limit FE Compatible 6947-C P04-2025", effective July 2025 · source

Independence Blue Cross: "On May 1, 2025, Independence Blue Cross (IBX) Select Drug Program® and Value Formularies ended coverage of Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA)." "This coverage change aligns with IBX's recent update to exclude coverage of weight loss drugs."

Independence Blue Cross, provider news 25-0038, effective May 2025 · source

Lilly's savings page, commercial insurance: "Zepbound® single-dose Pen Starting at $25 For up to a 3-month prescription with the Zepbound Savings Program", "Governmental beneficiaries excluded." The card requires that "You have been prescribed Zepbound® (tirzepatide) single-dose pen or Zepbound single-patient-use KwikPen® for an approved use consistent with FDA approved product labeling."

Eli Lilly and Company, Zepbound savings, effective September 2026 · source

The separate self-pay KwikPen card "is for self‑paying (cash) patients only": you agree that you "will not seek or accept reimbursement… from any third‑party payer, including private insurance or state or federal healthcare programs, nor apply those costs toward any deductible or true out‑of‑pocket requirements." Its eligibility list is residency in the United States or Puerto Rico and age 18 or older, with the same $299, $399 and $449 prices and "a maximum of up to 11 prescription fills per calendar year." On Lilly's savings page this option appears under the Medicare, "Government (other)" and "No insurance" choices.

Eli Lilly and Company, Zepbound self-pay KwikPen terms and conditions, effective August 2026 · source · savings page

LillyDirect lists the Zepbound KwikPen and the Zepbound vial each "Starting at $299/month", then $399 and $449 by dose, with the $449 price at 7.5 mg and above "with Zepbound Journey Program. Regular prices will apply if prescription is not refilled within 45 days ($499 for 7.5mg, $699…)". It lists the vial as "Exclusively available through LillyDirect | Self-pay only", and the single-dose pen as "Insurance accepted", "Pay as low as $25* per month for up to a 3-month prescription." It adds: "Savings are automatically applied through LillyDirect. If you choose to fill through another pharmacy, you may need a Lilly savings program depending on your insurance type."

Eli Lilly and Company, LillyDirect: Zepbound, effective August 2026 · source

CMS: the Bridge gives access "between July 1, 2026, and December 31, 2027." "Eligible beneficiaries will have a $50 copay … the Part D deductible will not apply, no part of the $50 copay counts towards the beneficiary's TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries."

Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, effective July 2026 · source

Zepbound and Saxenda came off the Contract Drugs List on January 1, 2026 and claims for them now deny regardless of what they were prescribed for. Wegovy stopped being eligible for weight loss on the same date. The state will still consider Zepbound for obstructive sleep apnea, and since April 1, 2026 Wegovy needs no prior authorization at all when it is prescribed for MASH.

California Department of Health Care Services, Medi-Cal Rx, effective April 2026 · source

Zepbound goes through sleep apnea. The criteria ask whether you are 18 or over, then whether you have "a diagnosis of moderate to severe obstructive sleep apnea (OSA)," then whether you have "an apnea-hypopnea index (AHI) of at least 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT)," and then about a diagnosis of obesity. An initial approval runs 180 days. To renew it you have to show results: "Has the client lost or maintained a loss of at least 5% from their baseline weight?"

Texas Prior Authorization Program Clinical Criteria, Zepbound (Tirzepatide), effective May 2026 · source